Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Mol. Neurosci.

Sec. Molecular Signalling and Pathways

Volume 18 - 2025 | doi: 10.3389/fnmol.2025.1634536

This article is part of the Research TopicPeroxisomes and Nervous Tissues: Unraveling Their Physiologic and Pathologic RoleView all 5 articles

Pex1 Loss-of-Function in Zebrafish Is Viable and Recapitulates Hallmarks of Zellweger Spectrum Disorders

Provisionally accepted
Ursula  Heins-MarroquinUrsula Heins-Marroquin1,2,3Zlatan  HodzicZlatan Hodzic1,2Beatriz  Soares Carneiro da SilvaBeatriz Soares Carneiro da Silva1,2Agnes  HendriksAgnes Hendriks1,2Floriane  GavottoFloriane Gavotto1,2Marc  O. WarmoesMarc O. Warmoes1,2Lisa  SchlickerLisa Schlicker1,2Samy  OmriSamy Omri4Christian  JägerChristian Jäger1,2Enrico  GlaabEnrico Glaab1,2Nancy  Elise BravermanNancy Elise Braverman5Maria Lorena  Cordero-MaldonadoMaria Lorena Cordero-Maldonado1,2Carole  L. LinsterCarole L. Linster1,2*
  • 1Luxembourg Centre for System Biomedicine, University of Luxembourg, Luxembourg, Luxembourg, Luxembourg
  • 2University of Luxembourg, Luxembourg, Luxembourg
  • 3University Medical Center Utrecht, Utrecht, Netherlands, Netherlands
  • 4Research Institute of the McGill University Health Centre, Montreal, Canada
  • 5Division of Medical Genetics, Department of Pediatrics and Human Genetics, McGill University, Montreal, Canada, Montreal, Canada

The final, formatted version of the article will be published soon.

Zellweger Spectrum Disorders (ZSDs) are rare autosomal conditions belonging to the larger group of peroxisome biogenesis disorders. The most prevalent form of ZSD is caused by mutations in the PEX1 gene, which encodes a AAA ATPase protein. Cells lacking functional PEX1 fail to import proteins crucial for the formation of competent peroxisomes, resulting in aberrant structures called ghost peroxisomes. Peroxisome dysfunction leads to the accumulation of compounds that are normally metabolized in this compartment, including very long-chain fatty acids (VLCFAs), pristanic and phytanic acids, as well as deficiency in compounds that are normally formed in this organelle, including docosahexaenoic acid (DHA) and plasmalogen precursors. Patients with a complete lack of PEX1 function develop severe symptoms and have a poor prognosis, with death in the first year of life. In the absence of effective treatments for ZSD, advancing our understanding of this complex multisystem disorder remains essential for uncovering new therapeutic opportunities. To this end, we generated and characterized a zebrafish model with Pex1 loss-of-function. Surprisingly, despite the early onset of disease-relevant features, about 10% of pex1-/- zebrafish reached adulthood. However, this resilience was short-lived, as none of the mutant fish survived beyond one year. Histopathological analysis of the liver in adult pex1-/- mutants revealed a profound peroxisomal import deficiency and severe vacuolation. Moreover, key metabolic hallmarks of ZSDs, including accumulation of VLCFAs and methyl-branched fatty acids phytanic and pristanic acid, were consistently detected in larval and adult pex1-/- mutants. Transcriptomics analysis in pex1-/- larvae revealed upregulation of ER-stress responses and pexophagy, as well as dysregulation of neurophysiological processes and visual perception. The latter findings were corroborated by abnormal locomotor behavior in the larvae and by disrupted outer nuclear and retinal layer architecture in adult mutant animals. The described zebrafish pex1 model provides a versatile in vivo platform to uncover novel disease-relevant pathways in ZSD and to investigate the physiological impact of VLCFAs and methyl-branched fatty acids. Its relative tolerance to Pex1 loss-of-function circumvents the early lethality observed in mouse models, enabling the study of ZSD pathophysiology beyond early developmental stages and offering a valuable tool for preclinical therapeutic exploration.

Keywords: Zebrafish, Pex1, peroxisome biogenesis disorders, Very long-chain fatty acids, phytanicacid, Pristanic acid, DHA, disease modeling

Received: 24 May 2025; Accepted: 13 Oct 2025.

Copyright: © 2025 Heins-Marroquin, Hodzic, Soares Carneiro da Silva, Hendriks, Gavotto, Warmoes, Schlicker, Omri, Jäger, Glaab, Braverman, Cordero-Maldonado and Linster. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Carole L. Linster, carole.linster@uni.lu

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.